Treatment of IgA Nephropathy in Pediatric Patients

Initial Management: RAS Blockade

The American Journal of Kidney Diseases recommends starting ACE inhibitor or ARB therapy in pediatric patients with IgA nephropathy when proteinuria is between 0.5-1 g/day per 1.73 m², and escalating to corticosteroids only if proteinuria persists >1 g/day per 1.73 m² after 3-6 months of optimized RAS blockade 1, 2
The American Journal of Kidney Diseases suggests beginning ACE-I or ARB when proteinuria is 0.5-1 g/day per 1.73 m², with mandatory treatment when proteinuria exceeds 1 g/day per 1.73 m² and up-titration based on blood pressure tolerance 1, 2
Target proteinuria reduction to <1 g/day per 1.73 m² rather than complete normalization, as attempting to reach <0.5 g/day increases side effects without proven benefit 3, 4
Maintain blood pressure below the 90th percentile for age and gender, with a target of 130/80 mmHg when proteinuria is <1 g/day and 125/75 mmHg when proteinuria exceeds 1 g/day 1, 2

Add a 6-month course of corticosteroid therapy when proteinuria persists >1 g/day per 1.73 m² despite 3-6 months of optimized ACE-I/ARB therapy, GFR remains >50 ml/min per 1.73 m², and patient has preserved renal function to justify growth-related risks 1, 2, 5, 6
Use either IV methylprednisolone or oral prednisone/prednisolone, with evidence-based protocols including 1 gram daily for 3 consecutive days at months 1, 3, and 5, or starting 0.8-1 mg/kg/day for 2 months and tapering by 0.2 mg/kg/day monthly for 4 months 1

Define crescentic IgA nephropathy as >50% of glomeruli with crescents on biopsy plus rapidly progressive renal deterioration, and treat with high-dose IV methylprednisolone plus cyclophosphamide 1, 6, 7
Treat minimal change disease with mesangial IgA deposits as minimal change disease when nephrotic patients show pathological findings of MCD with mesangial IgA deposits on kidney biopsy 6, 7

Mycophenolate mofetil is not recommended due to no demonstrated benefit 6
Corticosteroids combined with cyclophosphamide or azathioprine are not recommended unless crescentic disease 6
Fish oil, antiplatelet agents, tonsillectomy, and any immunosuppression when GFR <30 ml/min per 1.73 m² are not recommended due to insufficient evidence or unless crescentic disease 6, 7